[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336452-105":59,"doc-detail-336452-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sex-differences-in-the-survival-of-patients-with-neuroendocrine-neoplasms-a-comparative-study-of-two-national-databases","Sex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases","","Neuroendocrine neoplasms (NENs) show rising incidence globally, and prior UK analysis reported a female survival advantage across most tumour sites. This study validates those findings by comparing two national cancer databases, using identical statistical approaches. Data comprised 14,834 NCRAS and 108,399 SEER patients. Sixty-month survival by anatomical site was estimated with RMST and Kaplan–Meier methods, then female survival advantage was derived and compared.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sex-differences-in-the-survival-of-patients-with-neuroendocrine-neoplasms-a-comparative-study-of-two-national-databases/336452/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sex-differences-in-the-survival-of-patients-with-neuroendocrine-neoplasms-a-comparative-study-of-two-national-databases/336452.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the study address about sex differences?","Question",{"text":112,"@type":113},"The study compares whether female patients have better survival for neuroendocrine neoplasms than male patients, and whether this pattern seen in the UK database also appears in the US database.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which databases were used to validate the findings?",{"text":117,"@type":113},"The UK National Cancer Registration and Analysis Service (NCRAS) findings were compared with the US Surveillance, Epidemiology, and End Results Program (SEER) database using the same statistical framework.",{"name":119,"@type":110,"acceptedAnswer":120},"How was survival analyzed in the study?",{"text":121,"@type":113},"Sixty-month survival for males and females by anatomical site was calculated using restricted mean survival time (RMST) and Kaplan–Meier survival estimates, and then female survival advantage was derived.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336452,1790156207,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","cancers   \nArticle  \nSex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases  \nMohamed Mortagy 1,2, *, Marie Line El Asmar 3, Kandiah Chandrakumaran 4 and John Ramage 3,5,6  \nCitation: Mortagy, M.; El Asmar, M.L.; Chandrakumaran, K.; Ramage, J. Sex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases. Cancers 2024, 16, 2376. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cancers16132376](10.3390/cancers16132376)  \nAcademic Editors: Jill S. Barnholtz-Sloan, Kristin A. Waite and Sarah S. Jackson  \nReceived: 1 June 2024  \nRevised: 23 June 2024  \nAccepted: 24 June 2024  \nPublished: 28 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Hampshire Hospitals NHS Foundation Trust, Winchester SO22 5DG, UK  \n2 Internal Medicine Department, St. George University School of Medicine, West Indies, Grenada  \n3 Gastroenterology Department, Hampshire Hospitals NHS Foundation Trust, Basingstoke RG24 9NA, UK; [marieline.elasmar@hhft.nhs.uk](marieline.elasmar@hhft.nhs.uk) (M.L.E.A.)  \n4 Peritoneal Malignancy Institute, Hampshire Hospitals NHS Foundation Trust, Basingstoke RG24 9NA, UK; [kandiah.chandrakumaran@hhft.nhs.uk](kandiah.chandrakumaran@hhft.nhs.uk)  \n5 Faculty of Health and Wellbeing, University of Winchester, Winchester SO22 4NR, UK  \n6 Kings Health Partners Neuroendocrine Centre, London SE1 9RT, UK  \n* [Correspondence: mohamed.mortagy2@hhft.nhs.uk](Correspondence: mohamed.mortagy2@hhft.nhs.uk)  \nSimple Summary: Neuroendocrine neoplasms (NENs) are occurring more frequently worldwide. Data from the UK cancer database (National Cancer Registration and Analysis Service (NCRAS)) showed that female patients have better survival with neuroendocrine neoplasms. This study used the U.S. cancer database (Surveillance, Epidemiology, and End Results Program (SEER)) to validate and compare these ﬁndings. Sixty-months survival for NENs were calculated for both male and female patients from NCRAS and SEER. The ﬁndings from NCRAS were conﬁrmed by the ﬁndings from SEER that females survive more than males with NENs, mainly with lung and stomach NENs. The reason behind this is unclear and remains unexplained.  \nAbstract: Background: Neuroendocrine neoplasms (NENs) are increasing in incidence globally. Previous analysis of the UK cancer database (National Cancer Registration and Analysis Service (NCRAS)) showed a notable female survival advantage in most tumour sites. This study aims to compare NCRAS to the Surveillance, Epidemiology, and End Results Program (SEER) to validate these results using the same statistical methods. Methods: A total of 14,834 and 108,399 patients with NENs were extracted from NCRAS and SEER, respectively. Sixty-months survival for both males and females for each anatomical site of NENs were calculated using restricted mean survival time (RMST) and Kaplan–Meier Survival estimates. The sixty-month RMST female survival advantage (FSA) was calculated. Results: FSA was similar in NCRAS and SEER. The highest FSA occurred in lung and stomach NENs. Conclusions: The data from SEER conﬁrm the ﬁndings published by NCRAS. Female survival advantage remains unexplained.  \nKeywords: neuroendocrine tumour; neuroendocrine carcinoma; epidemiology; sex differences; cancer survival  \n1. Introduction  \nNeuroendocrine neoplasms (NENs) consist of well-differentiated Neuroendocrine tumours (NETs) and poorly differentiated Neuroendocrine carcinomas (NECs) [1] . The incidence of NENs is increasing worldwide, with a global incidence rate ranging from 3.16 to 10 per 100,000 [2–7] . While no sign","cbCainqjYU4KFAIj","https://ap.wps.com/l/cbCainqjYU4KFAIj","pdf",1160797,17,"English","# Introduction\n## Study Rationale and Background\n## Statistical Methods and Comparison Approach\n# Methods\n## Patient Data Sources\n## Survival Estimation (RMST and Kaplan–Meier)\n# Results\n## Female Survival Advantage by Site\n# Conclusions","[{\"question\":\"What question does the study address about sex differences?\",\"answer\":\"The study compares whether female patients have better survival for neuroendocrine neoplasms than male patients, and whether this pattern seen in the UK database also appears in the US database.\"},{\"question\":\"Which databases were used to validate the findings?\",\"answer\":\"The UK National Cancer Registration and Analysis Service (NCRAS) findings were compared with the US Surveillance, Epidemiology, and End Results Program (SEER) database using the same statistical framework.\"},{\"question\":\"How was survival analyzed in the study?\",\"answer\":\"Sixty-month survival for males and females by anatomical site was calculated using restricted mean survival time (RMST) and Kaplan–Meier survival estimates, and then female survival advantage was derived.\"}]","Sex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases | PDF",1790015103,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2201fca534275e9b8fbef9129fc69fa.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38584ded07221aa2fcba1b31d20d77c8.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f8fc387c502be5991eb91eb7adab983.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57f5e365fbc4d8fe279fc8164e585e26.webp",980,1385]